이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NuGen Medical Devices 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ian Heynen

최고 경영자

CA$74.4k

총 보상

CEO 급여 비율	100.0%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ian Heynen 의 보수는 NuGen Medical Devices 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CA$8m
Mar 31 2024	n/a	n/a	-CA$9m
Dec 31 2023	CA$74k	CA$74k	-CA$9m

보상 대 시장: Ian 의 총 보상 ($USD 54.48K ) Canadian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 175.39K ).

보상과 수익: Ian 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Ian Heynen

less than a year

테뉴어

CA$74,413

보상

Mr. Ian Heynen serves as CEO at NuGen Medical Devices Inc. since November 01, 2023. He serves as the Chief Financial Officer of Sentinelle Medical, Inc. Mr. Heynen has strong operating and financial leader...

리더십 팀

이름	위치	테뉴어	보상	소유권
Anthony Di Benedetto	Executive Chairman	1.6yrs	CA$150.00k	1.04% CA$ 249.1k
Ian Heynen	Chief Executive Officer	less than a year	CA$74.41k	데이터 없음
Richard Buzbuzian	President & Director	1.6yrs	CA$315.00k	3.11% CA$ 744.4k
Veronique Laberge	CFO & Secretary	1.5yrs	CA$183.00k	0.34% CA$ 82.5k
Nicky Canton	Executive VP & COO	no data	CA$211.97k	0.046% CA$ 11.0k
Karen Dunlap	Interim Chief Customer Officer & Director	1.8yrs	CA$142.80k	0.069% CA$ 16.5k
Elisha Dillon	Head of Global Sales & Strategic Partnerships	2.8yrs	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: NGMD 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Anthony Di Benedetto	Executive Chairman	1.6yrs	CA$150.00k	1.04% CA$ 249.1k
Richard Buzbuzian	President & Director	1.6yrs	CA$315.00k	3.11% CA$ 744.4k
Karen Dunlap	Interim Chief Customer Officer & Director	2.9yrs	CA$142.80k	0.069% CA$ 16.5k
Christopher Irwin	Independent Director	1.3yrs	데이터 없음	0.21% CA$ 50.6k
Erik Emerson	Member of Advisory Board	1.9yrs	데이터 없음	데이터 없음
John Leombruno	Independent Director	2.9yrs	데이터 없음	2.43% CA$ 581.4k
Greg Gironda	Member of Advisory Board	2yrs	데이터 없음	데이터 없음
Philip Cortese	Independent Director	1.7yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 이사회: NGMD 의 이사회는 경험(평균 재직 기간 1.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

NuGen Medical Devices 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

NuGen Medical Devices Inc., Annual General Meeting, Aug 20, 2024

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

CEO, President & Director exercised options to buy CA$594k worth of stock.

Nugen Medical Devices Inc. Announces Executive Changes

Less than half of directors are independent

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

Recent updates

Second quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.015 loss in 2Q 2023)

NuGen Medical Devices Inc. announced that it expects to receive CAD 10 million in funding

NuGen Medical Devices Inc., Annual General Meeting, Aug 20, 2024

First quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.017 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.056 loss per share (vs CA$0.062 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.012 loss per share (vs CA$0.012 loss in 3Q 2022)

NuGen Medical Devices Inc. Announces Chief Executive Officer Changes

NuGen Medical Devices Inc. Presents New Data from Preliminary Trial That Semaglutide (Ozempic ) Is Chemically Stable After It Is Administered Through Nugen 's InsuJet Needle-Free Injection Device

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.016 loss in 2Q 2022)

New minor risk - Insider selling

CEO, President & Director exercised options to buy CA$594k worth of stock.

First quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 1Q 2022)

NuGen Medical Devices Inc. announced that it has received CAD 0.45 million in funding

Full year 2022 earnings released: CA$0.062 loss per share (vs CA$0.10 loss in FY 2021)

NuGen Medical Devices Inc. announced that it has received CAD 2.5 million in funding

NuGen Medical Devices Inc. announced that it has received CAD 0.125 million in funding

Nugen Medical Devices Inc. Announces Executive Changes

NuGen Medical Devices Inc. announced that it expects to receive CAD 3 million in funding

Less than half of directors are independent

Third quarter 2022 earnings released

NuGen Medical Devices Inc. Announces the Launch of Its InsuJet Needle-Free Injection Device in Canada

NuGen Medical Devices Inc. Welcomes Erik Emerson to Its Advisory Board

NuGen Medical Devices Inc. Appoints Greg Gironda to Its Advisory Board

NuGen Medical Devices Inc. announced that it has received CAD 0.640376 million in funding

Second quarter 2022 earnings released: CA$0.016 loss per share (vs CA$0.021 loss in 2Q 2021)

NuGen Medical Devices Inc. announced that it expects to receive CAD 0.4118 million in funding

Nugen M.D. Receives Additional Health Canada Approval for Insulin Specific Needle-Free Injection System

NuGen Medical Devices Inc. Launches PetJet Providing Needle-Free Injections for Domesticated Pets

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.013 loss in 1Q 2021)

NuGen Medical Devices Inc., Annual General Meeting, Jun 17, 2022

Independent Director recently bought CA$53k worth of stock

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Independent Director recently bought CA$304k worth of stock

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령